Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adamas One Corp. - Common Stock (NQ: JEWL )

0.5400 +0.0200 (+3.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Adamas One Corp. - Common Stock

10 Materials Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
The Great Coal-apse
'Shine bright like lab diamonds," or whatever Rihanna said. In today's day and age, a woman's best friend is being replaced with something remarkably similar but cheaper. 
Via Benzinga
Why Core & Main Are Trading Lower By 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 114% to $1.47. Palisade Bio transformed GI-focused pipeline through exclusive worldwide licensing agreement with Giiant Pharma, Inc. for multiple... 
Via Benzinga
How Lab-Grown Diamonds Are Disrupting The Legacy Of Luxury
Diamonds will never go out of style, no matter the occasion. These precious gems are one of the most sought-after, lavish gifts, brightening any recipient’s day. Diamonds just are–something so iconic,... 
Via Benzinga
TalkMarkets Announces Company Spotlight Featuring Adamas One
TalkMarkets.com announces a company spotlight series featuring Adamas One (NASDAQ: JEWL), a leading producer of lab-grown diamonds.rapidly 
Via News Direct
TalkMarkets Announces Company Spotlight Featuring Adamas One
TalkMarkets.com announces a company spotlight series featuring Adamas One (NASDAQ: JEWL), a leading producer of lab-grown diamonds. 
Via Talk Markets
Investing In Luxury: Adamas One Unlocks The Potential For Lab-Grown Diamonds
Adamas One (JEWL) is a highly profitable company. There is no lack of demand for lab-grown diamonds and the company has already been producing at full production capacity since March of this year. 
Via Talk Markets
Top 5 Materials Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the basic materials sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Insiders Buying Adamas One And 1 Other Penny Stock
The Nasdaq recorded gains for the fourth week in a row. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront... 
Via Benzinga
Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 115 stocks hit new 52-week lows. 
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.